Cyclophosphamide versus placebo in scleroderma lung disease

Article Abstract:

A double-blind, randomized, placebo-controlled trial was conducted to determine the effects of oral cyclophosphamide on lung function and health-related symptoms in patients with evidence of active alveolitis and scleroderma-related interstitial lung disease. It was found that one year of oral cyclophosphamide in patients with symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life.

Drug therapy, Quality of life, Systemic scleroderma, Scleroderma (Disease), Lung diseases

---

Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever

Article Abstract:

A study examines the efficacy of a short course of the antimicrobial agent doxycycline in preventing tick-borne relapsing fever (TBRF) after high-risk activities in an area where TBRF is endemic. Results demonstrate that treatment with doxycycline is safe and efficacious in preventing TBRF after suspected exposure to ticks in a high-risk environment.

Care and treatment, Diagnosis, Prevention, Jarisch-Herxheimer reaction

---

Similar abstracts:

• Abstracts: Hope for the treatment of intestinal scleroderma. Treatment of the antiphospholipid syndrome
• Abstracts: The effects of chronic lithium treatment on psychomotor performance related to driving
• Abstracts: Trichomoniasis: trends in diagnosis and management. Trichomoniasis: under control or undercontrolled? Diagnosis and assessment of sigmoidoceles

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.